<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; opportunities</title>
	<atom:link href="http://www.tapanray.in/tag/opportunities/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Navigating Potential US Tariffs: Challenges and AI-Driven Opportunities for Indian Pharma</title>
		<link>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma</link>
		<comments>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 09 Aug 2025 08:09:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[challenged]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10955</guid>
		<description><![CDATA[India’s pharmaceutical industry, reportedly supplying 47% of US generic drugs and exporting $27.9 billion in FY24, faces the threat of 10-25% US tariffs under a potential Trump policy. Major players like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Aurobindo, reportedly &#8230; <a href="http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2020: Learnings From A Yearlong Catastrophic Disruption And Crystal-Gazing 2021</title>
		<link>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021</link>
		<comments>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/#comments</comments>
		<pubDate>Mon, 28 Dec 2020 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2020]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[anti-infective]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[crystal-gazing]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[hubris]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[Meeting]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[new drugs]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[rollout]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10383</guid>
		<description><![CDATA[ Wishing All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2021 Just a few days left for the year 2020 to merge with history. It will be remembered by all &#8211; as a year of all-round catastrophic global disruption. &#8230; <a href="http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Not To Let Go This Never Before Opportunity To Reposition Itself</title>
		<link>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself</link>
		<comments>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/#comments</comments>
		<pubDate>Mon, 14 Dec 2020 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[competitors]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[holistic]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medical-marketing]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reposition]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[WHD]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10366</guid>
		<description><![CDATA[‘While the COVID-19 pandemic has placed unparalleled demands on modern healthcare systems, the industry’s response has vividly demonstrated its resilience and ability to bring innovations to market quickly.’ This appeared in the McKinsey &#38; Company article – ‘Healthcare innovation: Building on the gains &#8230; <a href="http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Taming Two Critical Covid Uncertainties For Pharma’s Sustainable Growth</title>
		<link>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth</link>
		<comments>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/#comments</comments>
		<pubDate>Mon, 28 Sep 2020 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cinvid-19]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infections]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[mutating]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pace-setting]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Taming]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[uncertainties]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10275</guid>
		<description><![CDATA[The reasons behind a great urgency of the Governments, besides high expectations of the general public, to have the ‘ultimate solution’ very soon, against the ongoing pandemic, are understandable. However, various media-hyped narratives on their clinical trials, and timeframe for &#8230; <a href="http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Honing Patient Outcomes With WHDs</title>
		<link>http://www.tapanray.in/hoing-patient-outcomes-with-whds/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hoing-patient-outcomes-with-whds</link>
		<comments>http://www.tapanray.in/hoing-patient-outcomes-with-whds/#comments</comments>
		<pubDate>Mon, 02 Dec 2019 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Democratization]]></category>
		<category><![CDATA[Devices]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Fitbit]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[honing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[penetration]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[wearable]]></category>
		<category><![CDATA[Wearables]]></category>
		<category><![CDATA[WHD]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9791</guid>
		<description><![CDATA[On November 01, 2019, San Francisco-based Fitbit, Inc. announced that it has entered into a definitive agreement to be acquired by Google LLC for approximately US$ 2.1 billion. Many believe, though, the value of Fitbit lies in the health data that its &#8230; <a href="http://www.tapanray.in/hoing-patient-outcomes-with-whds/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hoing-patient-outcomes-with-whds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deadly Climate Change Impact On Human Health: How Prepared Is India?</title>
		<link>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deadly-climate-change-impact-on-human-health-how-prepared-is-india</link>
		<comments>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/#comments</comments>
		<pubDate>Mon, 12 Aug 2019 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Ayushman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change. global]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[gainers]]></category>
		<category><![CDATA[greenhouse]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Paris]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researching]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[warming]]></category>
		<category><![CDATA[Zika]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9665</guid>
		<description><![CDATA[It’s not uncommon to find many people, including heads of countries, expressing their serious apprehensions in public, about the scary impact of climate change. Just the last year, on November 26, 2018, BBC News captured one of such incidences with the astonishing &#8230; <a href="http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilars: Creating new vistas of opportunities for Indian Bio Pharmaceutical players in the global market.</title>
		<link>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market</link>
		<comments>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/#comments</comments>
		<pubDate>Thu, 31 Dec 2009 01:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[vistas]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=682</guid>
		<description><![CDATA[Biosimilar or follow-on biologic drugs market is fast evolving across the world with varying degree of pace and stages of developments. The global market for Bio-pharmaceuticals was around US$ 120 billion in 2008, as reported by IMS. However, total turnover &#8230; <a href="http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A brief history of the Indian Patent System from Indian Pharmaceutical Industry perspective, the concerns and opportunities.</title>
		<link>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities</link>
		<comments>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 00:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[brief]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=742</guid>
		<description><![CDATA[Although a comprehensive Act on Patents and Designs allowing product patents of drugs came into force in India in 1911, the first Patents Act of India was enacted in 1856.This Act gave a head start to the global pharmaceutical companies &#8230; <a href="http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CRAMS opportunities – India is strongly poised, a time to leverage</title>
		<link>http://www.tapanray.in/crams-opportunities-india-is-strongly-poised-a-time-to-leverage/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=crams-opportunities-india-is-strongly-poised-a-time-to-leverage</link>
		<comments>http://www.tapanray.in/crams-opportunities-india-is-strongly-poised-a-time-to-leverage/#comments</comments>
		<pubDate>Mon, 07 Sep 2009 01:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=786</guid>
		<description><![CDATA[Cost containment pressures due to various factors have prompted the global pharmaceutical companies to contract out various research related and manufacturing activities, over a period of time, from Europe and North America to low cost destinations like India and China. &#8230; <a href="http://www.tapanray.in/crams-opportunities-india-is-strongly-poised-a-time-to-leverage/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/crams-opportunities-india-is-strongly-poised-a-time-to-leverage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative use of the new-age ‘Social cyber-media’ as a pharmaceutical marketing tool has the potential to open a goldmine of opportunities.</title>
		<link>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities</link>
		<comments>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/#comments</comments>
		<pubDate>Thu, 25 Jun 2009 01:30:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[goldmine]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[new-age]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tool]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=851</guid>
		<description><![CDATA[The new-age marketing tool: With more and more doctors not giving adequate time and even showing reluctance to meet the medical representatives and the important hospitals following suit, the global pharmaceutical companies are now in search of new marketing tools. &#8230; <a href="http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-use-of-the-new-age-social-cyber-media-as-a-pharmaceutical-marketing-tool-has-the-potential-to-open-a-goldmine-of-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
